Marinus seizure med fails at interim analysis; shares plummet
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
Ovid Therapeutics is ramping up its patent fight with Marinus Pharmaceuticals.
Marinus Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Marinus to Report Fourth Quarter and Full Year 2023 Financial Results
Marinus Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023